Bonesupport
BONESUPPORT HOLDING AB (publ) – Publishes Q2 2023 interim report
MAR
BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the second quarter 2023.
STRONG MOMENTUM FOR CERAMENT G IN THE US
APRIL – JUNE 2023
- Net sales increased by 88 percent (75 percent at constant exchange rates) and amounted to SEK 140.4 million (74.6).
- The North America (NA) segment reported a sales growth of 126 percent (107 percent at constant exchange rate).
- The Europe & Rest of the World (EUROW) segment reported a sales growth of 28 percent (24 percent at constant exchange rates).
- The gross margin amounted to 91.3 percent (89.0).
- Operating result before effects from the Group’s incentive programs amounted to SEK +13.6 million (-9.1). Reported operating result amounted to SEK +6.0 million (-14.9).
- Earnings per share before dilution were SEK +0.08 (-0.25).
- Earnings per share after dilution were SEK +0.08 (-0.25).
JANUARY – JUNE 2023
- Net sales increased by 85 percent (72 percent at constant exchange rates) and amounted to SEK 260.1 million (141.0).
- The North America (NA) segment reported a sales growth of 118 percent (100 percent at constant exchange rate).
- The Europe & Rest of the World (EUROW) segment reported a sales growth of 31 percent (27 percent at constant exchange rates).
- The gross margin amounted to 90.9 percent (89.7)
- Operating result before effects from the Group’s incentive programs amounted to SEK +18.2 million (-21.6). Reported operating result amounted to SEK +6.7 million (-31.3).
- Earnings per share before dilution were SEK +0.09 (-0.51).
- Earnings per share after dilution were SEK +0.08 (-0.51).
"Strong quarter, with increased market penetration for CERAMENT G." Emil Billbäck, CEO
EVENTS DURING THE REPORTING PERIOD
- In May, a study was published of 53 patients, with an average follow-up time of 30 months, in which 100 percent of patients were able to avoid amputation when using CERAMENT G/V in the treatment of complex diabetic foot osteomyelitis cases.
- Strong long-term data with CERAMENT G for severe open fractures were presented in a study from Manchester University Hospital in May. The study was conducted with 81 patients with a mean follow-up time of 55.8 months.
EVENTS AFTER THE REPORTING PERIOD
Nothing to report.
Datum | 2023-07-13, kl 08:00 |
Källa | MFN |
![](https://static.allaaktier.se/ads/hand-waving-2.png)